Janneke S Hoogstad-van Evert

7PUBLICATIONS
27CO-AUTHORS
Obstetrics and gynaecologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 03, 2026
Menstrual Effluent Derived Immune Cell Composition Is Distinct in Women Using Contraceptives: A Pilot Study.

Aysel Gurbanova, Anne Stoverink, Imke M B van Wandeloo

|May 14, 2025
Feasibility and Effects of Implementing Multimodal Prehabilitation Before Cytoreductive Surgery in Patients with Ovarian Cancer: The Gynofit Multicenter Study.

Stella van der Graaff, Tessa A M Backhuijs, Frank P de Kort

|May 28, 2022
The Promises of Natural Killer Cell Therapy in Endometriosis.

Janneke Hoogstad-van Evert, Romy Paap, Annemiek Nap

|Oct 07, 2021
CD34+ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rgnull mice.

Jolien M R Van der Meer, Paul K J D de Jonge, Anniek B van der Waart

|Sep 15, 2021
Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells.

J M R Van der Meer, R J A Maas, K Guldevall

|Nov 23, 2020
TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer.

Ralph Ja Maas, Janneke S Hoogstad-van Evert, Jolien Mr Van der Meer

Pageof 2

Frequent Collaborators

4 joint publications

Jolien Mr Van der Meer

4 joint publications

Ralph Ja Maas

4 joint publications

Harry Dolstra

4 joint publications

Willemijn Hobo